The Male to Female Ratio in Treatment-Warranted Retinopathy of Prematurity: A Systematic Review and Meta-analysis.

Autor:	Hoyek S; Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston., Peacker BL; Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston., Acaba-Berrocal LA; Department of Ophthalmology, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago., Al-Khersan H; Bascom Palmer Eye Institute, University of Miami Leonard M. Miller School of Medicine, Miami, Florida., Zhao Y; Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston., Hartnett ME; Department of Ophthalmology, University of Utah, Salt Lake City, Utah., Berrocal AM; Bascom Palmer Eye Institute, University of Miami Leonard M. Miller School of Medicine, Miami, Florida., Patel NA; Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston.
Jazyk:	angličtina
Zdroj:	JAMA ophthalmology [JAMA Ophthalmol] 2022 Nov 01; Vol. 140 (11), pp. 1110-1120.
DOI:	10.1001/jamaophthalmol.2022.3988
Abstrakt:	Importance: Literature and anecdotal evidence suggest a relationship between male sex and retinopathy of prematurity (ROP). It is not known whether a difference, if present, is sex-related pathophysiologic predisposition or sex difference in meeting ROP screening criteria. Objective: To evaluate the association of sex with the development of treatment-warranted ROP. Data Sources: PubMed, Embase, and Web of Science databases were searched from 2000 to 2022. The search strategy used keywords including retinopathy of prematurity or ROP or retrolental fibroplasia and treatment or anti-VEGF or bevacizumab or ranibizumab or aflibercept or conbercept or laser or cryotherapy and gender or sex or male or female and medical subject headings terms. Study Selection: All studies reporting on treatment with anti-vascular endothelial growth factor, laser photocoagulation, and/or cryotherapy for ROP were identified. Studies reporting sex distribution in the treatment group were included in the meta-analysis. Exclusion criteria included case reports, case series of fewer than 10 treated patients, systematic reviews, conference abstracts, letters to the editor, animal studies, and non-English records. Data Extraction and Synthesis: Two reviewers independently screened and extracted the data following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The proportions of treated male and female infants were combined using random-effects meta-analysis. Main Outcomes and Measures: Numbers and percentages of male and female infants treated for ROP. Results: Of 11 368 identified studies, 316 met inclusion criteria, yielding a total of 31 026 treated patients. A higher percentage of male infants were treated for ROP (55% [95% CI, 0.54%-0.55%]), with low heterogeneity between studies (I2 = 34%; P < .001). Thirty-eight studies reported sex distribution in the screened population (170 053 patients; 92 612 [53%] male vs 77 441 [47%] female). There was no significant difference in the odds of receiving treatment between screened male and female infants (pooled odds ratio, 1.04 [95% CI, 0.91-1.18]; P = .67). Conclusions and Relevance: More male infants are treated for ROP than female infants. This could be due to a known relative pathophysiological fragility of preterm male infants in addition to a difference in ROP screening rates, with more male infants meeting the criteria than female infants. These findings have implications for future studies and may prompt more careful clinical monitoring of male neonates.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu